Key Insights

Highlights

Success Rate

96% trial completion (above average)

Published Results

54 trials with published results (41%)

Research Maturity

105 completed trials (79% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

3.0%

4 terminated out of 133 trials

Success Rate

96.3%

+9.8% vs benchmark

Late-Stage Pipeline

54%

72 trials in Phase 3/4

Results Transparency

51%

54 of 105 completed with results

Key Signals

54 with results96% success

Data Visualizations

Phase Distribution

121Total
Not Applicable (9)
P 1 (7)
P 2 (33)
P 3 (43)
P 4 (29)

Trial Status

Completed105
Unknown12
Withdrawn5
Recruiting4
Terminated4
Active Not Recruiting1

Trial Success Rate

96.3%

Benchmark: 86.5%

Based on 105 completed trials

Clinical Trials (133)

Showing 20 of 20 trials
NCT04198740Recruiting

Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface

NCT06602739Phase 3CompletedPrimary

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

NCT07309432Phase 3RecruitingPrimary

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

NCT05186025Active Not Recruiting

Tyrosine Allergoid Paediatric and Adult Study

NCT01471184Not ApplicableCompleted

The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo

NCT07220408Phase 2RecruitingPrimary

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

NCT04622345Phase 2CompletedPrimary

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

NCT06602726Phase 3CompletedPrimary

A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

NCT06800274Phase 4CompletedPrimary

Clinical and Biological Evaluation of NAAGA Versus Azelastine Eye Drops in Allergic Subjects With Tear Film Dysfunction

NCT05815758Phase 3CompletedPrimary

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT06459219Not Yet Recruiting

Factors Determining Tolerance to Nasal Allergen Exposure With Advanced Age in a Subset of Birch Pollen Allergic Subjects

NCT03660878Phase 1CompletedPrimary

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT05579730Phase 3CompletedPrimary

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis

NCT03494504Phase 3CompletedPrimary

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

NCT04207736Phase 3CompletedPrimary

The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.

NCT06686472Phase 2RecruitingPrimary

Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis

NCT05969236Phase 1CompletedPrimary

A Study of MDI-1228_mesylate Ophthalmic Solution in Healthy Adults

NCT05839938Not ApplicableEnrolling By InvitationPrimary

The Role of Vitamin D in Corneal Epithelial Barrier Function, Ocular Microbiome, Ocular Inflammation, and Visual Acuity of Children With Allergic Conjunctivitis

NCT06293820Phase 2CompletedPrimary

A Study Of TL-925 For The Treatment of AC

NCT03861910Completed

Dietary Choice for the Management of Cow's Milk Allergy Influences Other Allergic Manifestations

Scroll to load more

Research Network

Activity Timeline